Apimeds shares surge 40.62% after-hours after FDA confirms Type C meeting for LT-100 development.

Apimeds Pharmaceuticals (APUS) surged 40.62% in after-hours trading following the announcement of a scheduled FDA Type C meeting to discuss LT-100 (Apitox), its non-opioid biologic candidate for osteoarthritis. The meeting, set for May 4, 2026, marks a critical step in aligning with the FDA on U.S. development strategies for the product, which is undergoing manufacturing enhancements. The collaboration with Lōkahi Therapeutics and the regulatory engagement underscore progress in advancing LT-100, previously approved in South Korea, toward potential U.S. commercialization. Management emphasized the meeting’s role in refining the therapeutic pathway and reducing patient burden, reinforcing confidence in the program’s development trajectory. The significant post-market rally reflects investor optimism about regulatory alignment and the asset’s therapeutic potential in a high-unmet-need market.